Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.

[1]  Jorge Cortes,et al.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.

[2]  D. P. Busuttil.  Prolonged imatinib‐induced myelosuppression in chronic myeloid leukaemia with an unusually long survival , 2007, International journal of laboratory hematology.

[3]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[4]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[5]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[6]  Gerhard Eisenbrand,et al.  Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine , 2004, Journal of Cancer Research and Clinical Oncology.

[7]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[8]  Zhijian Xiao,et al.  Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in China , 2002, Leukemia & lymphoma.

[9]  L. Meijer,et al.  Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest , 2001, Oncogene.

[10]  L. Meijer,et al.  Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells , 2001, British Journal of Cancer.

[11]  M. Baccarani,et al.  Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. , 2000, British journal of haematology.

[12]  Zhijian Xiao,et al.  Meisoindigo for the treatment of chronic myelogenous leukaemia , 2000, British journal of haematology.

[13]  M. Baccarani,et al.  Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α‐interferon , 2000 .

[14]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[15]  Doris Marko,et al.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases , 1999, Nature Cell Biology.

[16]  H. Kantarjian,et al.  Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Hasford,et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.

[18]  M. Baccarani,et al.  Long‐term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group , 1994 .

[19]  J. Tanzer,et al.  Chronic myelocytic leukaemia with unusual (27 years) complete remission terminating in acute undifferentiated leukaemia: a clinical and karyotypic study. , 1991, Leukemia.

[20]  S. Ferrari,et al.  Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival. , 1989, Leukemia.

[21]  H. Heimpel,et al.  Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. , 1988, Blood.

[22]  Mauro,et al.  Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. , 1985, Blood.

[23]  H. Walker,et al.  PROLONGED SURVIVAL IN CHRONIC GRANULOCYTIC LEUKAEMIA AFTER BUSULPHAN INDUCED HYPOPLASIA AND KARYOTYPE CONVERSION , 1985, British journal of haematology.

[24]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[25]  F. Mitelman,et al.  Remarkably long survival of a patient with Ph1-positive chronic myeloid leukemia and 5' bcr rearrangement. , 1990, Leukemia.